Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy (HBOT), breathing high-concentration oxygen in a pressurized chamber, is an established treatment for decompression sickness, carbon monoxide poisoning, and 12 other approved indications. It has separately been tested as a longevity intervention on the theory that intermittent high-oxygen exposure produces a hormetic adaptation that lengthens telomeres and clears senescent cells.

The two questions matter separately: does HBOT cause oxidative damage, and does it slow aging? The honest answer is both. Acute HBOT sessions raise oxidative stress and DNA damage. Repeated sessions upregulate antioxidant defenses so the net balance flips. The longevity signal on top of that adaptation is real but fragile.

The flagship study, by Hachmo, Hadanny, Efrati and colleagues, published in Aging in 2020, enrolled 30 healthy adults aged 64+ in a prospective single-arm trial. Sixty daily 90-minute sessions at 2 ATA on 100% oxygen. Telomere length in B cells rose about 20% and senescent CD28-negative T cells dropped [1]. There was no control group. The overall repeated-measures statistical test across all time points was F=4.663, p=0.06, just above the conventional significance threshold, even though several individual pairwise time-point comparisons reached significance. Reporting individually significant sub-comparisons alongside a non-significant overall test is an unusual analytical choice worth noting. A related skin-biopsy study in 13 men found increases in collagen density, elastic fibers and vessel density [2].

Acute oxidative damage from HBOT is well documented and consistent across three decades of studies. Dennog et al. 1996 in Mutagenesis found HBOT reproducibly increased DNA strand breaks in leukocytes of all test subjects immediately after the first session, with no detectable effect 24 hours later, and no damage after further sessions under the same protocol [3]. Speit et al. 1998 confirmed the same pattern and quantified that over 50% of the induced DNA damage was repaired within the first hour [4]. Üstündağ et al. 2012 in Toxicology in Vitro, with 100 patients, saw significant DNA strand-break increases after the first HBO session, normalization within 2 hours, and full return to baseline by the fifth session [5]. The pattern is consistent: HBOT delivers an acute oxidative signal that repairs rapidly and to which the body adapts within a handful of sessions.

This adaptation window explains why short courses give the damage without the benefit. Simsek et al. 2021 in Biomolecules reviewed HBOT and mitochondrial function and concluded: short HBOT (1-5 sessions) has been shown to have deleterious effects, while longer HBOT (20-30 sessions and more) has beneficial effects. After roughly 20 sessions antioxidant scavenger activity is elevated enough that mitochondrial function is preserved and even enhanced. This is the hyperoxic-hypoxic paradox: intermittent exposure with 22-23 hour recovery windows upregulates the defenses that continuous or overly long exposure would overwhelm [6].

A systematic review by Tessema et al. 2022 in Frontiers in Aging, PRISMA-registered, screened 1,699 articles and included 17 studies (9 RCTs, 6 non-randomized trials, 2 uncontrolled trials, spanning humans, cells, rats and insects). Methodological variation prevented a quantitative meta-analysis. The review identified signals in telomere length, HIF-1alpha targets and some age-related disease outcomes, but could not conclude that HBOT slows aging in a unified way [7]. An Örebro University thesis (Saeed & Abdelhadi 2024) reviewed six studies on HBOT and senescent cells and found half came from the Efrati group; broad independent replication of the telomere-lengthening finding remains limited [8].

Context for the oxidative-stress concern that circulates online: chronic or supra-therapeutic hyperoxia is genuinely harmful. Sundar et al. 2025 in the American Journal of Physiology found 50% oxygen for 2-7 days induced senescence in lung cells via mitochondrial ROS and ER stress, blocked by mitochondrial antioxidants [9]. Xuefei et al. 2021 in Frontiers Cell Dev Biol described how chronic hyperoxia drives bronchopulmonary dysplasia in preterm infants via mitochondrial dysfunction [10]. These findings describe continuous, prolonged hyperoxia (hours to days without recovery) not intermittent clinical HBOT protocols (60-90 minutes daily with 22-23 hours of normal air between sessions). Chen et al. 2026 in Med Gas Res add a nuance relevant to older users: when aging is coupled with impaired mitochondrial metabolism, even normal oxygen (21%) may become a state of relative oxygen excess. The dose-response of oxygen and aging is non-linear [11].

Who this does not work for, or where evidence is weakest: the flagship telomere study had no control group, N=30, and has not been independently replicated. The related skin study had 13 men. The mechanistic case for the hyperoxic-hypoxic paradox is coherent but not proof of long-term benefit. HBOT chambers carry real risks: oxygen toxicity, barotrauma to ears and sinuses, and rare seizure. People with untreated pneumothorax or certain lung conditions should not undergo HBOT.

Safety at approved clinical doses is well-documented. Cronjé & Meintjes 2017 in Advances in Wound Care described HBOT as among the safest therapies used today, with self-limiting side effects that can usually be avoided with adequate screening [12]. Costanzo et al. 2025 in Undersea Hyperb Med studied 69 patients aged 75+ across 1,799 sessions at 2.4-2.8 ATA: side effects in 20.3% (mostly barotrauma), no life-threatening events [13].

Plain takeaway: HBOT is not a documented longevity treatment, and it is also not a route to accelerated aging when delivered under approved clinical protocols. The two most common online claims about HBOT are both partially wrong. Short courses will give you the acute DNA-damage phase without the antioxidant upregulation that follows. Long courses under an Efrati-style protocol have one uncontrolled study suggesting telomere benefit, which is not yet enough to call the effect established.

Regulatory safety updates (verified 2026-08-30)

The FDA issued a Letter to Health Care Providers on August 25, 2025 about serious injuries and deaths from hyperbaric oxygen therapy (HBOT) devices, including recent fires with high-concentration oxygen. The letter tells providers to follow the manufacturer's instructions, use proper grounding, ensure fire-prevention measures, and confirm patient clothing is compatible with hyperbaric use. Cotton is recommended; wool and synthetics may build up static.

Health Canada issued a safety alert on June 16, 2026 about unauthorized soft-shelled hyperbaric chambers found in wellness centres. Health Canada names risks that include fire when combined with oxygen concentrators, suffocation, spread of infections between users, damage to ears, eyes, sinuses, lungs and teeth, and changes in blood sugar. No soft-shelled chamber has been authorized for sale in Canada; hard-shell chambers are proven for 14 specific conditions.

A MAUDE adverse event report filed March 23, 2026 for the OxyHealth Vitaeris 320 soft-shell chamber describes a patient reporting headache and lethargy after unlimited 1.5-hour daily sessions over three months, with measured CO2 of 3,444 ppm after leaving the chamber (retested 2,444 the next day). The report classifies the event as a serious injury and raises a concern about CO2 monitoring in the chamber.